Analysis of schizophrenia-related genes and electrophysiological measures reveals ZNF804A association with amplitude of P300b elicited by novel sounds by del Re, E C et al.
 
Analysis of schizophrenia-related genes and electrophysiological
measures reveals ZNF804A association with amplitude of P300b
elicited by novel sounds
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation del Re, E C, S E Bergen, R I Mesholam-Gately, M A
Niznikiewicz, J M Goldstein, T U Woo, M E Shenton, L J
Seidman, R W McCarley, and T L Petryshen. 2014. “Analysis of
schizophrenia-related genes and electrophysiological measures
reveals ZNF804A association with amplitude of P300b elicited
by novel sounds.” Translational Psychiatry 4 (1): e346.
doi:10.1038/tp.2013.117. http://dx.doi.org/10.1038/tp.2013.117.
Published Version doi:10.1038/tp.2013.117
Accessed February 19, 2015 3:17:18 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879666
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAOPEN
ORIGINAL ARTICLE
Analysis of schizophrenia-related genes and
electrophysiological measures reveals ZNF804A
association with amplitude of P300b elicited by novel sounds
EC del Re
1,2,12,S EB e r g e n
2,3,4,12, RI Mesholam-Gately
2,5, MA Niznikiewicz
1,2,J MG o l d s t e i n
6,7,8,T UW o o
2,9,10,M ES h e n t o n
1,11,L JS e i d m a n
2,5,8,
RW McCarley
1,2 and TL Petryshen
2,3
Several genes have recently been identiﬁed as risk factors for schizophrenia (SZ) by genome-wide association studies (GWAS),
including ZNF804A which is thought to function in transcriptional regulation. However, the downstream pathophysiological
changes that these genes confer remain to be elucidated. In 143 subjects (68 clinical high risk, ﬁrst episode or chronic cases; 75
controls), we examined the association between 21 genetic markers previously identiﬁed by SZ GWAS or associated with putative
intermediate phenotypes of SZ against three event-related potential (ERP) measures: mismatch negativity (MMN), amplitude of
P300 during an auditory oddball task, and P300 amplitude during an auditory novelty oddball task. Controlling for age and sex,
signiﬁcant genetic association surpassing Bonferroni correction was detected between ZNF804A marker rs1344706 and P300
amplitude elicited by novel sounds (beta=4.38, P=1.03×10
−4), which is thought to index orienting of attention to unexpected,
salient stimuli. Subsequent analyses revealed that the association was driven by the control subjects (beta=6.35, P=9.08×10
−5),
and that the risk allele was correlated with higher novel P300b amplitude, in contrast to the signiﬁcantly lower amplitude observed
in cases compared to controls. Novel P300b amplitude was signiﬁcantly correlated with a neurocognitive measure of auditory
attention under interference conditions, suggesting a relationship between novel P300b amplitude and higher-order attentional
processes. Our results suggest pleiotropic effects of ZNF804A on risk for SZ and neural mechanisms that are indexed by the novel
P300b ERP component.
Translational Psychiatry (2014) 4, e346; doi:10.1038/tp.2013.117; published online 14 January 2014
INTRODUCTION
The genetic contribution to developing SZ is relatively high, with
heritability estimates of 81% by meta-analysis of twin studies
1 and
64% by a large family-based study.
2 Recent efforts to identify
genetic risk loci in order to gain insight into SZ pathophysiology
have involved GWAS with increasing success, and nearly 20 loci
have now been associated with SZ.
3 One of the ﬁrst genes to be
identiﬁed with genome-wide signiﬁcant evidence was ZNF804A, a
brain-expressed gene that encodes a zinc ﬁnger domain indicat-
ing a transcriptional regulatory function. ZNF804A was initially
implicated in risk of SZ and psychosis by a GWAS, and
subsequently replicated by several targeted association
studies.
4–10 A report of stronger association in SZ cases with
higher IQ suggests that variation in ZNF804A may confer risk of a
disease subtype with relatively preserved cognition.
11
Impaired cognitive functioning based on neuropsychological
tests, alterations in neuroanatomy and brain dysfunction as
measured by structural and functional neuroimaging, and
electrophysiological changes are all associated with SZ. In
addition, impairments are also frequently observed in unaffected
relatives, suggesting that these traits may represent heritable
intermediate phenotypes that could be used to decipher disease
pathology.
12,13 Event-related potentials (ERPs) reﬂect pre- and
post-synaptic activity in neurons, and index normal and patholo-
gical brain processes in real time.
14 Several ERPs are considered to
be intermediate phenotypes of SZ, with amplitude or latency
abnormalities observed in affected individuals and unaffected
relatives.
15–17 This includes the novel P300 component elicited
~300ms after complex, ‘novel’ sounds in an oddball sequence,
18
which is reported to have abnormal amplitude in SZ and high-risk
subjects.
19,20 Further, evidence of P300 deﬁcits in healthy siblings
of affected subjects
21,22 provides support for the novel P300 ERP
component being an intermediate phenotype of SZ.
The novel P300 is thought to represent a brain mechanism
involved in the rapid orienting of attention to events that are
unexpected, salient and contextually novel.
23–25 Detection of
novel stimuli involves, among other areas, the anterior cingulate,
26
followed by engagement of other brain regions important for
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27 notably the dorsola-
teral prefrontal cortex and the hippocampus.
18,28–30 Menon and
Uddin
31 have proposed a model whereby the anterior cingulate
response to a novel stimulus is preceded by ampliﬁcation of the
salient event by the insula. Both brain regions deﬁne the ‘salience
network’ that is important in dynamic switching between central-
executive and default mode networks in processes mediating
detection of salient events and capturing of attention.
32
Several candidate genes have been studied within the context
of association with ERP components and other putative inter-
mediate phenotypes of SZ. Catechol-O-methyltransferase (COMT)
has been associated with auditory oddball P300 amplitude in SZ
subjects, unaffected relatives and healthy individuals.
33,34 Neur-
egulin 1 (NRG1) is reported to be associated with latency of the
auditory oddball P300 component,
35,36 while its receptor, ERBB4,
has been related to reaction time in a visual oddball task.
37
Dysbindin 1 (DTNBP1) has been associated with amplitude of the
P1 component in a visual ERP task.
38 Other genes have been
associated with cognitive domains that are impaired in SZ,
including GRIN2B,
39 KIBRA,
40 MTHFR
41 and DISC1.
42 Several genes
identiﬁed in recent GWAS of SZ, including ZNF804A, have also
been investigated for relationships with cognitive performance,
neuroanatomical features and neural connectivity that are
abnormal in SZ.
11,43–45
In the present study, we sought to examine the genetic
contribution to ERP abnormalities as putative intermediate
phenotypes of SZ to gain insight into the biological pathways
that mediate brain dysfunction in this disorder. We explored
associations between well-characterized electrophysiological com-
ponents and genes with strong prior evidence of contributing to
risk of SZ by GWAS or to variation of putative intermediate
phenotypes. The primary focus of this article is P300b peak
amplitude evoked during an auditory novelty oddball task
(denoted hereafter as novel P300b), because it was the only ERP
component displaying a genetic association surpassing statistical
signiﬁcance after correction for multiple tests. We also explored
the relationship between the novel P300b component and
experimental neurocognitive measures of auditory attention and
working memory as a means of linking novel P300 to cognitive
and brain functions important in SZ. Our analyses indicate that the
ZNF804A gene previously implicated in risk for SZ is signiﬁcantly
associated with novel P300b amplitude in a pleiotropic manner
that may be independent from its contribution to SZ.
MATERIALS AND METHODS
Subjects
Subjects were recruited through the Boston CIDAR study (www.bostonci-
dar.org). The sample (N=143) utilized in this study consisted of a total of
68 cases, including 27 individuals with clinical high risk (CHR) or putatively
prodromal symptoms, 25 persons within the ﬁrst episode of schizophrenia
(FESZ), and 16 people with chronic schizophrenia (CSZ), as well as 75
healthy control participants. Patients were recruited by referrals from
clinicians or through local hospitals and clinics, and controls were recruited
through newspaper and website advertisements. The study was approved
by the local IRB committees at Harvard Medical School, Beth Israel
Deaconess Medical Center, Massachusetts General Hospital, Brigham and
Women’s Hospital and the Veteran Affairs Boston Healthcare System
(Brockton campus). All study participants, or legal guardians for those
under 18 years of age, gave written informed consent and received
payment for participation.
DSM-IV diagnoses were based on interviews with the Structured Clinical
Interview for DSM-IV-TR (SCID), Research Version (First et al., 2002) and
information from patient medical records. All FESZ participants met DSM-
IV-TR criteria for SZ, schizoaffective disorder or schizophreniform disorder,
and none had more than one year of continuous antipsychotic treatment.
CSZ participants met DSM-IV-TR criteria for SZ or schizoaffective disorder
and had an illness duration of at least ﬁve years. Inclusion criteria for CHR
subjects incorporated different approaches. The majority (N=23) were
categorized with ‘late prodromal syndromes’ as classiﬁed by the Criteria of
Prodromal States
46 based on the Scale of Prodromal Symptoms.
47 The
other four CHR participants were categorized with ‘early prodromal
syndromes’, which are more subtle and require wider criteria for
deﬁnition,
48 and include the so-called basic symptoms
49,50 and schizotypal
personality disorder.
48,51 Antipsychotic medication use was estimated
using chlorpromazine equivalents calculated according to Stoll.
52
Controls were drawn from the same geographic bases with comparable
age, gender, race and ethnicity, handedness, and parental socioeconomic
status evaluated using the Hollingshead two-factor index.
53 Controls were
ascertained to be comparable to each of the CHR, FESZ and CSZ groups.
Exclusion criteria for controls included any current or past major DSM-IV-TR
Axis I disorder, developmental disorders, psychiatric hospitalizations,
prodromal symptoms, schizotypal or other Cluster A personality disorders,
a ﬁrst degree relative with psychosis, or current or past use of
antipsychotics. Sleeping aids or anxiolytic agents for occasional use were
acceptable, as well as other past psychotropic medication use if not within
the prior 6 months.
Exclusion criteria for all subjects included sensory-motor handicaps,
neurological disorders, medical illnesses that signiﬁcantly impair neuro-
cognitive function, diagnosis of intellectual disability (IQo70), not ﬂuent in
English, DSM-IV substance abuse within the past month or dependence
within the past 3 months, current suicidality, or history of electroconvulsive
therapy for controls or electroconvulsive therapy within the past 5 years
for cases.
ERP tasks
Three different auditory tasks were employed: the novelty oddball, the
classical oddball and the mismatch negativity (MMN). The latter two tasks
were performed as detailed in McCarley et al.
54 and Niznikiewicz et al.,
55
respectively, and are not described here. As explained above, we have
focused on the novel P300b given its association with genetic data.
Novelty oddball task
Subjects performed a novelty, 3-stimulus auditory oddball task over
4 minutes. Stimuli (N=180) included brief tones (82ms duration, 75 dB
sound pressure level), with 20% (36) infrequent target tones (1.5kHz) and
60% (108) frequent standard tones (1kHz), as well as 20% (36) infrequent
non-target novel stimuli (300–320ms duration, 75 dB sound pressure level)
consisting of six different complex environmental sounds (for example,
dog bark, door slamming).
18 The inter-stimulus interval was 976ms (onset-
to-onset). Subjects were instructed to silently count the target tones.
EEG recording and processing
The EEG was recorded with a Biosemi Active-Two system using sintered
Ag/AgCl electrodes in an electrode cap at 64 standard scalp sites (DC-100
Hz bandpass ﬁlter, 512Hz digitization rate) with DC offsets kept below
25mV. During data acquisition, all channels were referred to the system’s
internal loop (CMS/DRL sensors located in the parietal region). The bipolar
vertical electro-oculogram was derived from electrode Fp1 and an
electrode below the left eye. The horizontal electro-oculogram was
derived from electrodes on the left and right outer canthi.
The EEG data were processed using the BrainVision Analyzer package,
version 2.0 (Brain Products GmbH, Munich, Germany). The continuous EEG
recordings were segmented from −100 to 900ms relative to stimulus onset
and re-referenced to the algebraic sum of the left and right mastoids.
Ocular correction was performed using the method of Gratton et al.
56
Epochs with artifacts exceeding +/−100μV with a maximal allowed
difference of 200μV were excluded. Average ERPs were computed from
the artifact-free epochs for each subject separately for each type of
stimulus and baseline corrected with a pre-stimulus baseline of −100 to 0
ms following digital ﬁltering (0–16Hz). The number of epochs included in
the average novel P300b ERP across all subjects was 33.6±2.99 (cases,
33.4±3.2; controls, 34.1±2.5; F(1,141)=2.1, P=0.147).
ERP analyses
In the novelty oddball task, the peak amplitude of the novel P300 peak
elicited by novel sounds was measured at electrode sites F1/Fz/F2 (frontal),
C1/Cz/C2 (central), and P1/Pz/P2 (parietal). The latency range for selecting
the peak in individual subject data was determined by visual inspection of
the grand average ERPs, and all electrodes of interest were inspected to
ensure that the same component was selected at each site. The novel P300
waveform in these data was biphasic (Figure 1), with an early peak, novel
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designate as novel P300b, between 315–390ms. Amplitude of the P300a
peak was highest at central sites, while the P300b peak was highest at
central and parietal sites (Figure 1). Thus, novel P300b amplitude at the Pz
electrode was chosen for genetic analyses to avoid overlap with the scalp
distribution of novel P300a amplitude.
Neuropsychological tests
Subjects were administered a large neurocognitive test battery including
tests estimating premorbid IQ (the Reading subtest from the Wide Range
Achievement Test-4 (WRAT-4);
57 and current IQ (the Vocabulary and Block
Design T-scores of the Wechsler Abbreviated Scale of Intelligence (WASI).
58
The ‘vigilance’, ‘working memory’ and ‘working memory plus interference’
measures from the Seidman auditory continuous performance test battery
(ACPT)
59,60 were utilized to assess different components of auditory
attention. All three auditory measures utilize letters of the alphabet
presented on an audiotape at a rate of one per second for 90 seconds, with
three blocks for vigilance and two blocks each for the two working
memory conditions (10.5min total). The vigilance measure taps sustained
auditory attention/vigilance by requiring a rapid response (tapping a
pencil) each time a letter ‘A’ immediately follows a letter ‘Q’ (QA vigilance).
The auditory working memory measure involves rapidly responding each
time a letter ‘A’ follows four letters after a letter ‘Q’ (Q3A memory). The
more complex and higher load working memory plus interference
condition (Q3A memory-interference) places increased demands on
working memory by invoking auditory working memory when confronted
with distracting/interfering information (that is, embedding distracting
combinations of ‘Q’, ‘A’ or ‘QA’ in between the cue ‘Q’ letters and the target
‘A’s that follow four letters after, thus dividing attention, preventing
counting and stressing the capacity to perform dual tracking). The hit rate
(% of correctly responding to the target letter ‘A’s) was determined for
each of the three conditions.
59,60
Statistical analyses of ERP data
Statistical analyses of ERP data were performed with SPSS v.19 (IBM,
Armonk, NY, USA). Novel P300b peak amplitude was analyzed using
MANOVA with group (all cases versus all controls) as a between factor, and
within factors of region (frontal/central/parietal) and site (F1/Fz/F2, C1/Cz/
C2, P1/Pz/P2). We also assessed differences between diagnostic subgroups
by comparing CHR, FESZ, and their matched controls, and comparing CSZ
and their matched controls, using the MANOVA design described above.
As IQ and pSES were signiﬁcantly different between cases versus controls,
the MANOVA was carried out with and without IQ and pSES as covariates;
however, results did not differ, therefore only results without covarying for
IQ and pSES are reported. Bonferroni-corrected P-values are reported.
Spearman’s rho correlations were calculated between novel P300b
amplitude at the Pz electrode and three measures from the Seidman ACPT,
‘vigilance’, ‘working memory’ and ‘working memory plus interference’.T h e
contributions of IQ and higher-order cognitive processes to novel P300b
amplitude were further examined by entering current IQ and ‘working
memory with interference’ performance as independent variables in a multiple
regression model with novel P300b amplitude as the dependent variable.
Genotyping and quality control
Blood or, in some instances, saliva was collected from all subjects at the
time of recruitment. DNA was extracted, quantiﬁed using Invitrogen's
Quant-iT (TM) dsDNA Assay Kit (Life Technologies, Carlsbad, CA, USA) and
stored at −80°C. Genotyping was conducted at the Broad Institute of
Massachusetts Institute of Technology and Harvard using the Illumina
OmniExpress array (Illumina, Inc., San Diego, CA, USA) containing 733202
single-nucleotide polymorphisms (SNPs). Quality control steps were
performed on the full data using PLINK
61 as follows: SNPs were removed
if they had o1% minor allele frequency, o95% genotyping rate,
deviation from Hardy−Weinberg equilibrium (Po1×10
−6), or differential
missingness between cases and controls at the SNP or haplotype level.
Three subjects with low genotyping rates (o90%) and/or high hetero-
zygosity values (>34%) were removed. SNPs not directly genotyped were
imputed with Beagle software
62 using HapMap3 reference panels
containing >1.2 million markers.
63 All imputed SNPs included in
association analyses were imputed with high conﬁdence (Info >0.85).
Genetic markers
Thirteen SNPs conferring risk for SZ identiﬁed by published GWAS
64–67 and
surpassing a genome-wide signiﬁcance threshold
68 of Po5×10
−8 were
selected. SNPs meeting this criterion but with minor allele frequencies
o10% were excluded due to too few minor allele carriers in this sample.
In addition, eight SNPs in candidate genes were included that have
prior evidence from at least two studies for association with SZ inter-
mediate phenotypes, including ERP abnormalities (COMT
33), neuropsycho-
logical impairments (ERBB4,
37,69,70 MTHFR,
71,72 DISC1,
42 COMT,
69,73 KIBRA,
40
NRG1,
69 GRIN2B
69), and structural and functional neuroimaging measures
(DTNBP1,
74,75 DISC1,
42,76 NRG1,
76 GRIN2B,
77 ERBB4,
37 COMT,
78 KIBRA
79).
We identiﬁed a total of 21 SNPs meeting these selection criteria
(Supplementary Table 1).
Figure 1. Novel P300 waveforms. Left: topographic map illustrating the central−parietal scalp distribution of novel P300b amplitude
measured at latency between 315−390 ms and waveforms at the midline electrodes (Fz, Cz and Pz) in controls and cases combined (N=143).
Right: novelty P300b oddball task grand average waveforms in controls (N=75) and in cases (N=68) at the midline electrodes (Fz, Cz and Pz).
Color distribution of topographical maps corresponds to novel P300b amplitude between 0 and 10 μV.
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Genetic association analyses were performed using linear regression in
PLINK with covariates accounting for sex and age, as well as population
substructure captured by the ﬁrst ﬁve multidimensional scaling compo-
nents. Diagnostic subgroup (CHR, FESZ, CSZ and control) likely impacts
true performance differences, but it is also a potential confounding
variable since medication and other environmental conditions may differ
by group. Accordingly, main analyses were conducted without diagnostic
subgroup as a covariate, and results were subsequently conﬁrmed in
analyses with diagnostic subgroup as a covariate in the model. The
following ERP components were tested: MMN at the Fz electrode, oddball
P300 amplitude at the Cz electrode, and novel P300b amplitude at the Pz
electrode. Bonferroni correction was applied to the genetic association
results, not accounting for potential correlations between the ERP
variables, to yield a study-wide signiﬁcance threshold of Po7.9×10
−4
for the three ERP variables and 21 SNPs tested. As current IQ and pSES
differed signiﬁcantly by ZNF804A genotype, novel P300b amplitude was
analyzed using MANCOVA with genotype as a between factor and pSES
and current IQ as covariates. Post hoc analyses exploring the strength of
ZNF804A association were conducted separately by diagnostic subgroup,
sex and genetically deﬁned Caucasian ancestry (the largest ancestral
population within this sample, N=87). Genetic association tests between
ZNF804A and current IQ and a measure of auditory attention (Seidman
ACPT ‘working memory plus interference’) were also conducted.
RESULTS
Subject characteristics
Sample demographic data are summarized in Table 1. Most
variables did not differ between controls and cases (combined
CHR, FESZ and CSZ), with the exception of current IQ (F
(1,141)=9.5; Po0.01), years of formal education (F(1,141)=4.6;
Po0.05), parental socioeconomic status (F(1,141)=4.35, Po0.05)
and global assessment of functioning (GAF) score (F(1,136)=485,
Po0.01). As the cases were a composite of three diagnostic
groups, Supplementary Table 2 reports demographic data for CHR
and FESZ cases both matched to their control group, and for CSZ
cases matched to their control group.
Novel P300b amplitude is signiﬁcantly reduced in SZ cases
MANOVA revealed a main effect of group (all cases versus all
controls) on novel P300b amplitude (F(1,141)=26.2; Po0.001),
which was signiﬁcantly lower in cases than controls (Figure 1;
Supplementary Table 3). There was also a main effect of brain
region (F(2,140)=74.0, Po0.001), but no interaction of region by
group (F(2,140)=0.02, P=0.98). Post hoc analysis revealed higher
P300b amplitude at parietal and central regions (both Po0.001)
relative to frontal (Figure 1), therefore, genetic association
analyses utilized novel P300b amplitude data at the Pz electrode.
In analyses of the diagnostic subgroups (Supplementary Figure 1),
a main effect of group was also found in the MANOVA comparing
CHR, FESZ and their matched controls (F(2,107)=7.0, Po0.01).
Post hoc analysis revealed no difference in amplitude between
CHR and FESZ groups (P=0.99), with both groups signiﬁcantly
lower than controls (Po0.01). The lack of amplitude differences
between CHR and FESZ justiﬁed inclusion of CHR subjects as cases
in all analyses. MANOVA of CSZ and matched controls also
revealed a main effect of group (F(1,31)=15.5; Po0.001).
Relationship between novel P300b and attention to auditory
stimuli
In order to better understand the neural substrates of novel
P300b, we examined its relationship with higher-order cognitive
processes. As the auditory novel P300 paradigm is thought to
index salience detection, we investigated performance in the
Seidman ACPT task that indexes sustained and selective attention
to auditory stimuli. We examined three measures, ‘vigilance’,
‘working memory’ and ‘working memory plus interference’.
Performance on all three tasks was signiﬁcantly impaired in cases
relative to controls (Supplementary Table 3). While novel P300b
amplitude was not signiﬁcantly correlated with the vigilance or
working memory measures (rho=0.17, P=0.21 and rho=0.21,
P=0.06, respectively) a signiﬁcant correlation was found for the
‘working memory plus interference’ measure (rho=0.4, Po0.001;
Supplementary Figure 2).
To further examine this relationship, ‘working memory with
interference’ performance and current IQ were entered as
independent variables in a multiple regression model with novel
P300b amplitude as the dependent variable. The model was
statistically signiﬁcant (F(2,133)=12.3, P=0.0005), explaining
14.4% of the variance in novel P300b amplitude. Only ‘working
memory with interference’ signiﬁcantly contributed to the model
(beta=0.3; P=0.001), suggesting a relationship between novel
P300b amplitude and higher-order attentional processes. IQ did
not signiﬁcantly contribute to the model (beta=0.113; P=0.24),
therefore it was not included as a covariate in subsequent genetic
association analyses.
Signiﬁcant association between ZNF804A and novel P300b
amplitude
Genetic association analyses of 21 SNPs conferring risk for SZ or
impacting putative intermediate phenotypes were performed for
each of the three ERP variables, MMN (Fz), oddball P300 amplitude
(Cz), and novel P300b amplitude (Pz) (Supplementary Table 4). The
only result to attain study-wide signiﬁcance (that is, Po7.9×10
−4)
was between the ZNF804A marker, rs1344706, and novel P300b
Table 1. Sociodemographic and clinical information
Controls (N=75) Cases (N=68) P-value rs1344706
AA (N=66) AC (N=54) CC (N=23) P-value
Age 26.1 (10.5) 26.4 (12.0) NS 27.0 (11.8) 25.3 (10.6) 26.2 (11.4) NS
Male/Female 46/29 49/19 NS 40/26 39/15 16/7 NS
Premorbid IQ 114.6 (15.4) 110.9 (16.3) NS 111.0 (15.1) 115.6 (15.4) 111.8 (18.7) NS
Current IQ 117.8 (14.0) 110.3 (15.0) o0.01 110.8 (15.5) 118.4 (12.4) 114.4 (16.9) o0.05
Education 13.9 (2.7) 12.9 (2.7) o0.05 13.5 (2.7) 13.4 (2.8) 13.4 (2.7) NS
pSES 1.8 (0.9) 2.1 (1.0) o0.05 2.2 (1.1) 1.7 (0.77) 1.91 (0.9) o0.05
GAF 84.5 (7.7) 49.2 (11.0) o0.01 66.0 (20.5) 70.9 (19) 62.7 (20.9) NS
CPZ equivalents NA 248.8 (214.7) NA 343.1 (269.6) 160.2 (118.8) 189.3 (123.6) NS
Abbreviations: CPZ, chlorpromazine; GAF, global assessment of functioning; NA, not applicable; NS, not signiﬁcant; pSES, parental socioeconomic status. CPZ
equivalents were calculated for subjects on antipsychotic medication (N=36, including 9 CHR, 14 FESZ and 13 CSZ subjects). Values are mean (s.d.). Fisher’s
Exact Test was used for categorical variables and ANOVA for continuous variables (P>0.05).
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−4; Table 2), explaining 7.2%
of the total variance. The ‘A’ allele for this A/C SNP, which has
previously been associated with increased risk for SZ and
psychosis, was associated with higher novel P300b amplitude
(Figure 2). Since diagnostic group could be a potentially
confounding variable, analyses including group (CHR, FESZ,
CSZ and controls) as a covariate were also performed, but this
had a negligible effect on the results (beta=4.21, P=1.38×10
−4).
Therefore, subsequent post hoc analyses did not include
diagnostic group as a covariate. In addition, MANCOVA of P300b
amplitude with genotype as a between factor and pSES and
current IQ as covariates revealed a main effect of genotype
(F(2,138)=3.64, P=0.029) and no interaction effect of the
covariates, indicating that these variables are not confounding
the ZNF804A association. Amplitude was signiﬁcantly lower in CC
genotype than AA (Po0.05), while amplitude of AA and AC did
not differ (P=0.99).
Association analyses of only cases or only controls revealed that
the ZNF804A association was strongly driven by the control
subjects (beta=6.35, P=9.08×10
−5), with little contribution from
the cases when CHR, FESZ and CSZ diagnostic groups were
analyzed separately or together (Table 2). Association results were
similar between males and females. Restricting analyses to
participants of Caucasian ancestry (N=87), the largest ancestry
group represented in this study, yielded a relatively similar effect
size (beta=3.34; P=0.012) as in the entire study population
(beta=4.38).
We also examined whether the association detected between
ZNF804A and novel P300b amplitude at the Pz electrode was
supported by analyses of other electrodes. Associations were
detected with novel P300b amplitude at other parietal, central and
frontal electrodes (4.2×10
−4oPo0.064; Figure 3), although the
Table 2. Association analyses for ZNF804A SNP rs1344706 and novel
P300b amplitude
Group N Beta P-value
All subjects 143 4.38 1.03×10
−4
Combined cases 68 1.97 0.21
CHR 27 2.75 0.33
FESZ 25 0.88 0.74
CSZ 16 3.21 0.61
Controls 75 6.35 9.08×10
−5
Abbreviations: CHR, clinical high risk; CSZ, chronic schizophrenia; FESZ, ﬁrst
episode of schizophrenia.
Figure 2. ZNF804A rs1344706 association with novel P300b amplitude. Left: scatterplot of novel P300b amplitude at the Pz electrode by
rs1344706 genotype in controls (black dots) and cases (red dots). Horizontal lines depict average amplitude in controls or cases. Right: novelty
oddball task grand average waveforms at the Pz electrode by genotype in controls (top panel; black lines) and in cases (bottom panel; red
lines).
Figure 3. Distribution of ZNF804A rs1344706 association with novel
P300b amplitude in controls. Rs1344706 association results with
novel P300b amplitude at latency between 315−390 msec are
shown for frontal, central and parietal electrodes (uncorrected
P-values above electrode labels). Correlation between novel P300b
amplitude at the Pz electrode and amplitudes at other electrodes
(Spearman’s rho values below electrode labels) decreases stepwise
from parietal to central to frontal sites as the strength of rs1344706
association with novel P300b amplitude decreases (that is, less
signiﬁcant P-values). All Spearman’s rho correlations signiﬁcant at
Po0.01.
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of the ZNF804A association with novel P300b amplitude
decreased from parietal sites (P1, Pz, P2) to central sites (C1, Cz,
C2) to frontal sites (F1, Fz, F2), paralleling the stepwise decrease in
the correlations between novel P300b amplitude at the Pz
electrode and amplitudes at central and frontal electrode sites
(Figure 3). These results suggest that the ZNF804A association
may be more speciﬁc for mechanisms indexed by novel P300b
amplitude at parietal sites.
DISCUSSION
ZNF804A was among the ﬁrst genes associated with risk of SZ by
GWAS with statistical evidence surpassing genome-wide
signiﬁcance.
4,7 The ‘A’ allele of SNP rs1344706 in ZNF804A was
associated with increased risk of psychosis, with an odds ratio of
1.11 in a combined analysis of SZ and bipolar disorder.
4
Subsequent studies focused on ZNF804A strongly supported
association with SZ.
5–11 ZNF804A is expressed in the brain, and the
risk allele of rs1344706 has been associated with decreased mRNA
expression during fetal brain development.
80 Knockdown of
ZNF804A in neural progenitor cells changes expression of genes
pertaining to neuronal outgrowth and migration, synapse forma-
tion, and cell adhesion, all of which have been implicated in the
pathophysiology of SZ.
81 Animal and cell culture studies have
shown that ZNF804A is associated with expression of COMT, an
enzyme that degrades catecholamines, and the DRD2 dopamine
receptor.
82 These data provide a possible link between novel P300,
ZNF804A and dopaminergic signaling, as there is evidence that
the novel P300 ERP component is mediated by catecholaminergic
activity.
83 In silico studies have also suggested possible involve-
ment of ZNF804A in regulation of oligodendrocyte proliferation
and differentiation.
84 This might impact neural connectivity, and
in fact ZNF804A has been associated with connectivity between
brain regions that are important in processing of auditory
stimuli.
18,27–30,85
The present investigation detected signiﬁcant association
between ZNF804A and amplitude of the P300b electrophysiolo-
gical component elicited by a novelty oddball task. The novel
P300 component represents a brain mechanism dedicated to
re-orienting attention to salient and novel events in the
environment.
24,25 Novel P300 is of particular interest since SZ is
characterized by core cognitive deﬁcits, notably, general difﬁculty
in concentrating attention on relevant stimuli while ignoring
unimportant stimuli,
86 including during the CHR period.
87,88
Indeed, the cases in our study exhibited lower P300b amplitude
compared to controls, which is supported by prior reports of high-
risk, recent onset, and chronic SZ subjects.
19,20,89,90 Interestingly,
we found that the risk-associated allele of rs1344706 was related
to increased novel P300b amplitude, in contrast to the lower
amplitude observed in SZ cases. This result implies that ZNF804A
has pleiotropic effects on ERPs and SZ, in that the allele associated
with increased risk of SZ is also related to higher P300b amplitude,
opposite to that observed in SZ. Previous studies have also
suggested that genes implicated in SZ etiology may exhibit
pleiotropic effects on intermediate phenotypes including ERPs,
gray matter volume, cognitive performance and sensorimotor
gating.
11,44,69,91 While this study is limited by a small sample size
and mixed population that may increase the likelihood of false
positive results, our ﬁndings are supported by those of O’Donoghue
et al.
92 (this issue), who found a remarkably similar relationship
between the rs13444706 risk allele and increased P300 amplitude
elicited by an auditory oddball task. Although O’Donoghue et al. did
not utilize the same novel oddball task, both oddball P300 and novel
P300 are elicited in response to rare, deviant and salient
stimuli.
26,93,94 Therefore, their results strongly support our ﬁndings
and provide independent evidence for pleiotropic effects of
ZNF804A on SZ and regulation of brain processes mediating ERPs.
Our ﬁnding of association with novel P300b amplitude in
controls but not in cases, which was also observed by
O’Donoghue et al.,
92 could be due to several factors. One potential
scenario is that the brain pathology present in individuals at high
risk or diagnosed with SZ may disrupt the ZNF804A effect on P300
amplitude and thereby mask the association with elevated P300
amplitude in cases. It is also possible that other genetic,
epigenetic and environmental risk factors that are highly loaded
in cases but not controls inﬂuence ERPs such that the ZNF804A
effect is obscured. Alternatively, the small case- and control-only
samples had low statistical power, so failure to detect an
association in some analyses is not surprising. Additional studies
are needed to conﬁrm our ﬁndings, elucidate the function of
ZNF804A in SZ and brain function, and clarify its interaction with
other risk factors.
Investigation of the functional signiﬁcance of ZNF804A associa-
tion with SZ has focused on brain structure and connectivity
between neural circuits during performance of cognitive or
emotional tasks, domains particularly affected in SZ.
95,96 The risk
allele of rs1344706 is hypothesized to modulate connectivity
between the dorsolateral prefrontal cortex and hippocampus,
speciﬁcally during working memory tasks, in both healthy
controls
43,85 and SZ subjects.
97 These studies are pertinent to
our results, as they indicate that ZNF804A may modulate speciﬁc
neural circuitry that has been implicated in the dynamics of novel
P300.
18,27–30 As novel P300 indexes a complex dynamic process in
which detection of the novel event occurs via the anterior
cingulate,
26 among other regions, and habituation to the novel
event via recruitment of working memory through the dorsolat-
eral prefrontal cortex and hippocampus,
18,27–29 our genetic
association results with novel P300b are in line with published
studies demonstrating ZNF804A association with modulation of
connectivity between these brain regions.
85,97,98 Thus, the present
investigation supports the notion that ZNF804A regulates speciﬁc
and dynamic brain processes, possibly at the interface between
the salience and executive networks.
32,99
On reviewing the extant literature, some studies suggest that SZ
subjects carrying the rs1344706 risk allele may have milder
impairments than non-carriers. For example, SZ risk allele carriers
have larger regional gray matter volume and relatively intact
cognitive performance,
11 indicating that ZNF804A may delineate a
subtype of SZ with preserved brain function in some domains.
However, other studies have found greater impairment in SZ
subjects carrying the risk allele, including heightened psychotic
symptoms.
100 In healthy controls, risk allele carriers appear to be
more impaired, with impaired attention,
91 deleterious effects on
gray matter volume and cortical thickness and neural activity
reported in default network areas
45,91 and the Theory of Mind
network.
101 However, the latter studies only evaluated
controls, therefore it is unknown whether these deleterious
effects would also be observed in SZ subjects. It should also be
kept in mind that different approaches have been used across
studies (for example, grouping subjects of different genotypes)
and that correction for multiple testing has not consistently been
performed, which could result in inconsistent or spurious results.
Future studies of both SZ and healthy subjects across multiple
domains will be important in elucidating the role of ZNF804A in
brain function and risk of SZ.
In conclusion, our ﬁnding of signiﬁcant association
between ZNF804A and novel P300b amplitude concurs with prior
literature suggesting a speciﬁc role of this gene in modulating
brain circuits that are neurobiological substrates of this ERP
component.
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